Skip to main content
Premium Trial:

Request an Annual Quote

Richard Kent, Robert Dishman, Kevin Sanborn, William Emhiser

Premium

Richard Kent has become president and CEO of Serenex, based in Durham, NC. He succeeds Robert Dishman, the company’s founding president, CEO, and chairman.

Prior to joining Serenex, Kent was president and CEO of Ardent Pharmaceuticals. Before that, he held various positions at GlaxoSmith-Kline, including vice president for US medical operations, group medical director, vice president for global medical affairs, and chief medical officer.

Kent holds a BA from the University of California, Berkeley, and an MD from the University of California, San Diego, School of Medicine. He completed his training at Harvard University, Stanford University, and Duke University, and was on the medical staff at Duke University Medical Center before working at Burroughs Wellcome and Glaxo Wellcome in Research Triangle Park.

 

Kevin Sanborn has become president of Millipore’s life sciences divison, replacing William Emhiser. Previously, Sanborn was vice president of strategic planning and business development at Millipore, which is based in Bedford, Mass.

Prior to joining the company, Sanborn was a consultant at Bain & Company. Before that he was a financial analyst at Goldman, Sachs & Company. He holds an MBA from the Amos Tuck School of Business Administraton at Dartmouth College, and an AB in Economics from Bowdoin College.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.